Rani Therapeutics (NASDAQ:RANI - Free Report) had its price objective lifted by HC Wainwright from $12.00 to $13.00 in a research report released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock.
RANI has been the subject of a number of other research reports. Canaccord Genuity Group lowered their price objective on Rani Therapeutics from $21.00 to $9.00 and set a buy rating for the company in a research report on Wednesday, March 27th. Wedbush restated an outperform rating and issued a $8.00 price target on shares of Rani Therapeutics in a report on Tuesday, February 6th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and an average target price of $11.75.
Get Our Latest Stock Analysis on Rani Therapeutics
Rani Therapeutics Price Performance
Rani Therapeutics stock traded down $0.10 during midday trading on Tuesday, reaching $7.46. 148,051 shares of the company were exchanged, compared to its average volume of 127,664. The company has a market capitalization of $374.19 million, a price-to-earnings ratio of -5.74 and a beta of 0.33. The company has a debt-to-equity ratio of 0.96, a quick ratio of 6.36 and a current ratio of 6.36. The firm's 50-day simple moving average is $4.57 and its 200-day simple moving average is $3.47. Rani Therapeutics has a 1 year low of $1.82 and a 1 year high of $8.75.
Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.04. On average, analysts anticipate that Rani Therapeutics will post -0.94 EPS for the current year.
Rani Therapeutics Company Profile
(
Get Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Featured Articles
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
